Semon Dominique 4
4 · SUNESIS PHARMACEUTICALS INC · Filed Apr 26, 2010
Insider Transaction Report
Form 4
Semon Dominique
10% Owner
Transactions
- Exercise of In-Money
Options
2009-10-27−1,699,140→ 0 total(indirect: See footnotes)Exercise: $0.00From: 2009-04-30Exp: 2016-10-31→ Warrants (1,699,140 underlying) - Exercise of In-Money
Warrants
2009-10-27+1,699,140→ 5,097,440 total(indirect: See footnotes)Exercise: $0.22From: 2010-10-27Exp: 2016-10-31→ Common Stock (1,699,140 underlying) - Purchase
Options
2009-04-30+169,914→ 169,914 total(indirect: See footnotes)Exercise: $2.20From: 2009-04-30Exp: 2016-04-03→ Preferred Stock (169,914 underlying) - Purchase
Options
2009-04-30+1,699,140→ 1,699,140 total(indirect: See footnotes)Exercise: $0.00From: 2009-04-30Exp: 2016-04-03→ Warrants (1,699,140 underlying) - Sale
Common Stock
2009-12-11$2.02/sh−1,508,051$3,046,263→ 0 total(indirect: See footnotes) - Sale
Common Stock
2010-02-25$0.94/sh−793,803$747,604→ 2,604,497 total(indirect: See footnotes) - Exercise of In-Money
Options
2009-10-27−169,914→ 0 total(indirect: See footnotes)Exercise: $2.20From: 2009-04-30Exp: 2016-10-31→ Preferred Stock (169,914 underlying) - Exercise of In-Money
Warrants
2010-02-25$0.13/sh−3,398,300$424,788→ 1,699,140 total(indirect: See footnotes)Exercise: $0.22From: 2009-04-30Exp: 2016-04-03→ Common Stock (3,398,300 underlying) - Exercise of In-Money
Common Stock
2010-02-25$0.22/sh+3,398,300$747,626→ 3,398,300 total(indirect: See footnotes) - Exercise of In-Money
Preferred Stock
2009-10-27$2.20/sh+169,914$373,811→ 509,744 total(indirect: See footnotes)Exercise: $2.20From: 2010-10-27→ Common Stock (1,699,140 underlying) - Purchase
Warrants
2009-04-30$0.13/sh+3,398,300$424,788→ 3,398,300 total(indirect: See footnotes)Exercise: $0.22From: 2009-04-30Exp: 2016-04-03→ Common Stock (3,398,300 underlying)
Footnotes (6)
- [F1]On December 11, 2009 Nexus Gemini L.P. ("Gemini") and Merlin Nexus II, L.P. ("Nexus II") sold 1,000,000 and 508,051 shares of Common Stock, respectively.
- [F2]The Reporting Person is the managing member of Nexus Gemini Advisors, LLC and Merlin Biomed Private Equity Advisors, LLC, the investment advisors to Gemini, Nexus II, and Merlin Nexus III, L.P. ("the Funds"). The Funds own direct interests in the reported securities.
- [F3]The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F4]On April 30, 2009 Gemini and Nexus III acquired 1,399,300 and 1,999,000 warrants respectively. Each warrant was exercisable to purchase one share of common stock. On February 25, 2010 Gemini and Nexus III exercised 1,399,300 and 1,999,000 warrants, respectively, and thereby acquired 1,399,300 and 1,999,000 shares of common stock, respectively. Also on February 25, 2010, Gemini and Nexus III sold 326,860 and 466,943 shares of common stock, respectively.
- [F5]On April 30, 2009 Gemini and Nexus III acquired options to purchase preferred stock and warrants. Gemini's option allowed it to purchase 69,964 shares of preferred stock, each convertible into 10 shares of common stock, and 699,640 warrants, each exercisable to purchase one share of common stock. Nexus III's option allowed it to purchase 99,950 shares of preferred stock, each share convertible into 10 shares of common stock, and 999,500 warrants, each exercisable to purchase one share of common stock. On October 27, 2009 Gemini and Nexus III exercised their options to acquire, respectively, 699,640 and 999,500 warrants and 69,964 and 99,950 shares of preferred stock.
- [F6]No Expiration Date for these Preferred Shares.